3 reasons to target global healthcare in 2026 -expert

Should investors be buying healthcare shares this year?

Healthcare shares are one of the sectors that are largely underrepresented here in Australia. 

It makes up roughly 6% of the S&P/ASX 200 Index (ASX: XJO). 

By comparison, financials and materials make up more than 56%. 

This means that for investors wanting exposure to healthcare shares, looking at an international ETF can be a good option. 

A report from iShares suggests the long-term outlook is positive with policy headwinds easing.

Here are three reasons why now might be a good time to gain exposure to global healthcare shares. 

A group of people in a corporate setting do a collective high five.

Image source: Getty Images

Policy headwinds easing

According to iShares, US policy uncertainty saw valuations in healthcare suppressed at near 30-year lows in 2025.

However, the policy uncertainty that hung over the sector last year has now largely resolved. 

President Trump's Most Favored Nation executive order has spurred major drug companies to negotiate deals on medication pricing, and investor focus is swinging back to the sector's strong innovation pipeline. 

This sparked outperformance in the last quarter of 2025. 

Healthcare led all global sectors in Q4 – gaining more than 10% after President Trump's Most Favored Nation executive order prompted pharmaceutical giants such as Pfizer and Eli Lilly to negotiate pricing with the White House and helped to resolve uncertainty over US tariff policies.

Heavy investment

In the report from iShares, it said clear policy direction, alongside investor concerns regarding a possible technology sector bubble in the United States, prompted significant movement into healthcare investments toward the end of last year. 

In November 2025, ETFs targeting this sector experienced their largest monthly global inflows in five years, attracting US$6.8 billion across the industry. 

With clarity now emerging for what has recently been an unloved sector, we see an opportunity for investors to refocus on the positive fundamentals and long-term supportive trends that may propel healthcare forward in 2026.

Despite gaining momentum, iShares believes the sector is still undervalued.

With healthcare valuations still looking cheap relative to global equities – trading at around a 13% discount despite the recent performance surge – now may be the time for investors to consider adding more exposure to the sector.

AI buildout and defensive safety

While some sectors are being threatened by AI takeover, healthcare shares are being positively impacted by AI.

Industry experts said AI is now increasingly being used in hospitals to automate clinical notes, staffing rosters and billing, freeing up staff for more valuable tasks, and patient care. 

Additionally, AI is beginning to transform the medical research field, accelerating drug development from early studies to human trials and market launch.

The report also reinforced that, as well as offering opportunities to tap into innovation and some of the long-term 'mega forces' shaping the global economy today, healthcare exposure can provide additional benefits for those looking to build a diversified share portfolio.

How do investors gain exposure to global healthcare?

For investors looking to add this sector to their portfolio, here are three ASX ETFs to consider. 

The first is the iShares Global Healthcare ETF (ASX: IXJ). It tracks the performance of the S&P Global 1200 Healthcare Sector Index. This index includes small, mid, and large-cap biotechnology, healthcare, medical equipment, and pharmaceuticals companies.

Another option is the BetaShares Global Healthcare ETF – Currency Hedged (ASX: DRUG). 

It is made up of 60 of the largest global healthcare companies (outside of Australia). 

Finally, Vaneck Vectors Global Health Leaders ETF (ASX: HLTH) invests in 50 fundamentally sound and attractively valued companies with the best growth prospects in the healthcare sector.

Motley Fool contributor Aaron Bell has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Pfizer. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Two colleagues looking at a graph and comparing share prices.
Healthcare Shares

Telix vs Clinuvel Pharmaceuticals: Which ASX healthcare share deserves your next $1,000 of investment capital?

We compare Telix and Clinuvel Pharmaceuticals on valuation, dividends, and momentum—which ASX healthcare stock looks more compelling now?

Read more »

Numerous Australian dollar notes laid out.
Healthcare Shares

I'd buy 6,462 shares of this ASX stock to aim for $200 a month of passive income

This business can provide very healthy dividends.

Read more »

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

UBS thinks Telix Pharmaceuticals shares will go how high?

Good news out of the US has led to a share price target upgrade.

Read more »

Scientist taking down notes from a tablet, with two other scientists working in the background.
Healthcare Shares

Healius vs Australian Clinical Labs: Which ASX pathology share wins?

Healius and Australian Clinical Labs are both top pathology providers, but one stands out for profits, dividends, and recent momentum.

Read more »

Doctor looks at a graph on a tablet.
Healthcare Shares

Ramsay Health Care vs Sonic Healthcare: Which healthcare stock is better value?

Which offers better value — Ramsay Health Care or Sonic Healthcare? I compare their fundamentals, dividends, momentum and reveal my…

Read more »

A doctor looks unsure.
Healthcare Shares

CSL shares jump 93%: Is the ASX biotech stock a buy, sell or hold for October?

Can the CSL share price rebound keep going?

Read more »

Two doctors having a discussion about a patient diagnosis, holding digital tablet.
Healthcare Shares

Are CSL shares a buy after its big news?

I look at what CSL’s latest drug development deal could mean for the healthcare giant’s long-term growth.

Read more »

A female scientist in a laboratory setting using a tablet to review data, with a male scientist working in the background.
Healthcare Shares

ResMed vs Fisher & Paykel Healthcare: Which is better value?

How do ResMed and Fisher & Paykel compare on value, income, and share price momentum? Here’s my verdict on which…

Read more »